

# **BlackRock Health Sciences Opportunities Portfolio - Investor A Shares**

Release Date 03-31-25

Category Health


## **Investment Objective & Strategy**

#### From the investment's prospectus

The investment seeks to provide long-term growth of capital.

The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.

Past name(s): BlackRock Health Sciences Inv A.



13.25

0.62

0.77

0.71

0.75

Principal	Risks

3 Yr Std Dev


3 Yr Beta

Foreign Securities, Loss of Money, Not FDIC Insured, Country or Region, Market/Market Volatility, Equity Securities, Industry and Sector Investing, Management, Small Cap, Mid-Cap

# **Important Information**


Please refer to the Morningstar Disclosure and Glossary document contained in your plan's eligibility package for additional information. You may always access the most current version of the Disclosure and Glossary at https://www.voyaretirementplans.com/ fundonepagerscolor/DisclosureGlossary.pdf

Funds or their affiliates may pay compensation to Voya® affiliates offering a fund. Such compensation may be paid out of distribution, service and/or 12b-1 fees that are deducted from the fund's assets, and/or may be paid directly by the fund's affiliates. Any fees deducted from fund assets are discussed in the fund's prospectus and disclosed in the fund fact sheet. Because these fees are paid on an on-going basis, over time these fees will increase the cost of your investment and may cost you more than paying other types of sales charges. If offered through a retirement program, additional fees and expenses may be charged under that program. NOT A DEPOSIT. NOT FDIC INSURED. NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY. NOT GUARANTEED BY THE INSTITUTION. MAY GO DOWN IN VALUE.



<b>Top 10 Holdings</b> as of 02-28-25	% Assets
Eli Lilly and Co	11.22
Boston Scientific Corp	6.87
Intuitive Surgical Inc	5.34
AbbVie Inc	5.13
Abbott Laboratories	4.77
UnitedHealth Group Inc	3.90
Stryker Corp	3.47
Thermo Fisher Scientific Inc	2.98
Gilead Sciences Inc	2.91
Amgen Inc	2.83

BlackRock



Manaissantas Fassits Cantaga as of 02 20 25

Moi	Morningstar Equity Sectors as of 02-28-25		
·	Cyclical	0.13	
A	Basic Materials	0.00	
$\triangle$	Consumer Cyclical	0.00	
	Financial Services	0.13	
命	Real Estate	0.00	
W	Sensitive	0.00	
	Communication Services	0.00	
•	Energy	0.00	
<b>‡</b>	Industrials	0.00	
	Technology	0.00	
$\rightarrow$	Defensive	99.87	
Ħ	Consumer Defensive	0.00	
•	Healthcare	99.87	
•	Utilities	0.00	

Operations						
Gross Prosp Exp Ratio	1.09% of fund assets	Waiver Data	Type	Exp. Date	%	
Net Prosp Exp Ratio	1.09% of fund assets	_	_	_	_	
Management Fee	0.67%					
12b-1 Fee	0.25%	Portfolio Manager(s)				
Other Fee	0.00%	Erin Xie. Since 2003.				
Miscellaneous Fee(s)	0.17%	Xiang Liu. Since 2020.				
Fund Inception Date	12-21-99					
Total Fund Assets (\$mil)	7,161.1	Advisor BlackRock Advisors, LLC				
Annual Turnover Ratio %	27.00	Subadvisor	_			

## Notes

Fund Family Name

As described in the "Management of the Fund" section of the Fund's prospectus beginning on page 41, BlackRock has contractually agreed to waive the management fee with respect to any portion of the Fund's assets estimated to be attributable to investments in other equity and fixed-income mutual funds and exchange-traded funds managed by BlackRock or its affiliates that have a contractual management fee, through June 30, 2026. In addition, BlackRock has contractually agreed to waive its management fees by the amount of investment advisory fees the Fund pays to BlackRock indirectly through its investment in money market funds managed by BlackRock or its affiliates, through June 30, 2026. The contractual agreements may be terminated upon 90 days' notice by a majority of the non-interested trustees of the Trust or by a vote of a majority of the outstanding voting securities of the Fund.